Levi Gray-Rupp, PhD, on Using Integrated Circuit T-Cells Against Solid Tumors

Video

The senior director of immunology at Arsenal Bio discussed advantages of ICTs and the company’s clinical trial in ovarian cancer.

“Integrated circuit T-cells are cells that have a single transgene that we integrate using a non-viral CRISPR-based delivery method to a specific locus in the genome. And then that transgene encodes all of the different elements that we use to reprogram the cells to overcome various barriers to activity within solid tumors. And we really have a wide toolkit of technologies that we can deploy to address various challenges within solid tumors.”

Arsenal Bio’s answer to challenges in treating solid tumors is thecompany’s integrated circuit T-cell (ICT) platform, which is being used in 1 current clinical trial and multiple preclinical programs. Preclinical and clinical data on ICTs were presented at the World Oncology Cell Therapy Congress (WOCTC) held April 25-26 in Boston, Massachusetts, by Levi Gray-Rupp, PhD, senior director, immunology, Arsenal Bio.

CGTLive spoke with Gray-Rupp to learn more about ICTs, their properties, and their potential advantages in targeting and treating tumors. Some advantages include enabling a larger payload with non-viral, CRISPR delivery compared to viral delivery, and 2 shRNA modifications that are designed to reduce apoptosis in the tumor microenvironment and increase cell persistence, expansion, and antitumor activity.

He also touched on the clinical-stage ICT program in Arsenal’s pipeline, AB-1015, which is being evaluated in patients with platinum-resistant epithelial ovarian cancer in a currently enrolling phase 1 trial (NCT05617755) that dosed its first patient in January 2023. He also noted Arsenal’s second ICT program, AB-2100, which the company is planning to initiate a clinical trial for patients with kidney cancer in 2024.

Click here to read more coverage of WOCTC 2023.

REFERENCE
Grap-Rupp L. Integrated Circuit T cells (ICTs) for solid tumors. Presented at: WOCTC; April 25-26; Boston, Massachusetts.
Recent Videos
Robert Califf, MD, MACC, a cardiologist and former FDA commissioner
Natalie Goedeker, CPNP, on Handling Neuromuscular Gene Therapy at Real-World Sites
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
Michael Flanagan, PhD, chief scientific officer at Avidity
David Barrett, JD, the chief executive officer of ASGCT
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
David Barrett, JD, the chief executive officer of ASGCT
Alfred L. Garfall, MD, MS, associate professor of medicine (hematology-oncology) and director, Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program, Hospital of the University of Pennsylvania; and section chief, Multiple Myeloma, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Nirav Shah, MD, MSHP, associate professor of medicine, at the Medical College of Wisconsin
© 2025 MJH Life Sciences

All rights reserved.